Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interactive review guidance clarified

This article was originally published in The Gray Sheet

Executive Summary

Updated 1guidance released Feb. 28 on the "interactive review" process between FDA and companies removes from the "telephone calls" section a sentence which stated that FDA should confirm a company's email summarizing a phone discussion and commitments with an email of its own for the submission's administrative record. The updated guidance, which supersedes a Dec. 28, 2007, document, also removes the need for additional manufacturing procedures from the list of PMA "major issues" about which FDA should informally alert companies before sending formal notification (2"The Gray Sheet" Jan. 7, 2008, p. 6)

You may also be interested in...



FDA Gets “Interactive” In New Premarket Guidance Document

A Dec. 28 final FDA guidance document lays out a path for more informal interaction between agency reviewers and device companies while preserving CDRH's options to place holds on premarket reviews

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel